Over the last decade, the mouse anti-CD3E mAb, OKT3, has been evaluated in clinical trials for oral delivery to the gut for treatment of nonalcoholic steatohepatitis (NASH; NCT01205087), with results suggestive of clinical activity (Lalazar et al., 2015). The gene discussed is CD3E; the disease is metabolic dysfunction-associated steatohepatitis.